Dashboard
Manage Tickers

OCX Insight Molecular Diagnosti...


$ 5.79 $ -0.31 (-4.98 %)    

Wednesday, 29-Oct-2025 15:59:50 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 635.61 $ 0.00 (0 %)
DIA $ 475.44 $ 0.00 (0 %)
SPY $ 686.87 $ 0.00 (0 %)
TLT $ 90.89 $ 0.00 (0 %)
GLD $ 365.31 $ 0.00 (0 %)
$ 5.91
$ 6.15
$ 3.21 x 100
$ 8.30 x 1,944
-- - --
$ 1.92 - $ 6.76
104,876
na
na
$ 1.06
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

needham-reiterates-buy-on-oncocyte-maintains-425-price-target
Needham Reiterates Buy on OncoCyte, Mainta...
05/13/2025 11:52:03

Needham analyst Mike Matson reiterates OncoCyte (NASDAQ:OCX) with a Buy and maintains $4.25 price target.

oncocyte-q1-adj-eps-019-beats-023-estimate-sales-232m-beat-15450k-estimate
OncoCyte Q1 Adj. EPS $(0.19) Beats $(0.23)...
05/12/2025 20:09:01

OncoCyte (NASDAQ:OCX) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.23) by 17...

Core News & Articles
Earnings Scheduled For May 12, 2025
05/12/2025 08:32:31

oncocyte-announces-trial-progress-completes-trial-design-and-receives-irb-approval-says-within-coming-weeks-it-expects-to-welcome-three-transplant-centers-as-trial-participants
Oncocyte Announces Trial Progress, Complet...
04/30/2025 12:38:24

needham-reiterates-buy-on-oncocyte-maintains-425-price-target
Needham Reiterates Buy on OncoCyte, Mainta...
04/08/2025 12:18:16

Needham analyst Mike Matson reiterates OncoCyte (NASDAQ:OCX) with a Buy and maintains $4.25 price target.

12-health-care-stocks-moving-in-tuesdays-pre-market-session
12 Health Care Stocks Moving In Tuesday's ...
04/01/2025 12:05:42

lake-street-initiates-coverage-on-oncocyte-with-buy-rating-announces-price-target-of-5
Lake Street Initiates Coverage On OncoCyte...
03/28/2025 16:00:43

Lake Street analyst Thomas Flaten initiates coverage on OncoCyte (NASDAQ:OCX) with a Buy rating and announces Price Target o...

stephens--co-reiterates-equal-weight-on-oncocyte-maintains-4-price-target
Stephens & Co. Reiterates Equal-Weight on ...
03/26/2025 14:39:54

Stephens & Co. analyst Mason Carrico reiterates OncoCyte (NASDAQ:OCX) with a Equal-Weight and maintains $4 price target.

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
03/26/2025 12:11:54

stephens--co-reiterates-equal-weight-on-oncocyte-maintains-4-price-target
Stephens & Co. Reiterates Equal-Weight on ...
03/25/2025 14:45:49

Stephens & Co. analyst Mason Carrico reiterates OncoCyte (NASDAQ:OCX) with a Equal-Weight and maintains $4 price target.

needham-reiterates-buy-on-oncocyte-maintains-425-price-target
Needham Reiterates Buy on OncoCyte, Mainta...
03/25/2025 11:07:13

Needham analyst Mike Matson reiterates OncoCyte (NASDAQ:OCX) with a Buy and maintains $4.25 price target.

earnings-scheduled-for-march-24-2025
Earnings Scheduled For March 24, 2025
03/24/2025 08:32:08

oncocyte-prices-291m-equity-offering-at-205share
Oncocyte Prices $29.1M Equity Offering At ...
02/10/2025 13:43:10

oncocyte-announces-publication-of-data-regarding-determacni-assay
Oncocyte Announces Publication Of Data Reg...
12/04/2024 21:18:02

Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its...

oncocyte-announces-additional-favorable-data-regarding-its-lead-assay-vitagraftwhich-was-published-in-the-journal-nephrology-dialysis-transplantation
Oncocyte  Announces Additional Favorable D...
12/02/2024 21:17:52

Oncocyte first to published randomized interventional data to rule-in for biopsy in high-risk patient population Study shows th...

needham-reiterates-buy-on-oncocyte-maintains-425-price-target
Needham Reiterates Buy on OncoCyte, Mainta...
11/13/2024 11:59:01

Needham analyst Mike Matson reiterates OncoCyte (NASDAQ:OCX) with a Buy and maintains $4.25 price target.

oncocyte-q3-2024-adj-eps-041-beats-044-estimate-sales-115000k-miss-200000k-estimate
OncoCyte Q3 2024 Adj. EPS $(0.41) Beats $(...
11/12/2024 21:52:05

OncoCyte (NASDAQ:OCX) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.44) by 6....

earnings-scheduled-for-november-12-2024
Earnings Scheduled For November 12, 2024
11/12/2024 08:32:46

what-to-expect-from-oncocytes-earnings
What to Expect from OncoCyte's Earnings
11/11/2024 18:02:40

needham-reiterates-buy-on-oncocyte-maintains-425-price-target
Needham Reiterates Buy on OncoCyte, Mainta...
10/15/2024 09:41:03

Needham analyst Mike Matson reiterates OncoCyte (NASDAQ:OCX) with a Buy and maintains $4.25 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION